TMT-Rx (Torralva Medical Therapeutics)
TMT-Rx is a drug development company based in Portland, Oregon, focused on creating novel therapeutics to address the growing crisis of fentanyl and synthetic opioid overdose. Founded by Dr. Phillip R. Torralva, a board-certified anesthesiologist and addiction medicine specialist, the company is pioneering research into the unique mechanisms of fentanyl toxicity, particularly those resistant to current treatments like naloxone. TMT-Rx's mission is to increase survival from fentanyl overdose by developing next-generation therapeutics that target both opioid and non-opioid receptor mechanisms, with the vision of providing effective solutions for overdose reversal, medication-assisted treatment, and chemical weapon countermeasures.
Industries
N/A
Nr. of Employees
small (1-50)
Products
Patent portfolio for opioid/opiate prevention and reversal
Series of provisional, PCT and related patent filings covering compositions and methods for prevention and reversal of opioid/opiate overdose and related prophylaxis.
Patent portfolio for opioid/opiate prevention and reversal
Series of provisional, PCT and related patent filings covering compositions and methods for prevention and reversal of opioid/opiate overdose and related prophylaxis.
Expertise Areas
- Preclinical research and translational modeling
- Opioid pharmacology and toxicology
- Formulation development for intranasal and intramuscular delivery
- Drug discovery and candidate selection for overdose reversal
Key Technologies
- In vivo animal models for respiratory toxicity
- Endoscopic laryngeal/vocal cord imaging
- Receptor binding and functional pharmacology assays
- Molecular modeling of ligand-receptor interactions
Key People
Founder, Chief Executive Officer, Chief Scientific Officer
Vice President of Business Development
Director of Operations
Founder, Chief Executive Officer, Chief Scientific Officer
Vice President of Business Development
Director of Operations
News & Updates
TMT-Rx was launched in 2020 with an award from the National Institute on Drug Abuse 'Start a Substance Abuse Startup Challenge.'
TMT-Rx received a prestigious Phase I grant from the National Institutes of Health in 2021, supporting early-stage drug development.
In 2022, TMT-Rx was awarded NIDA STTR and SBIR FAST-track grants for drug development, supporting the advancement of its novel therapeutics.
TMT-Rx was selected for the I-Corps™ at NIH program and the NIH Fast-Track Small Business Innovation Research program, receiving over $1.3 million in funding to expedite commercialization of its biomedical technology.
TMT-Rx received a NIDA small business innovation research grant to investigate novel mechanisms for treatment of naloxone-resistant drug overdose.
Dr. Phillip Torralva was selected for the Yale Innovation to Impact Fellowship, a national program supporting commercialization of solutions to substance use disorder.
TMT-Rx was launched in 2020 with an award from the National Institute on Drug Abuse 'Start a Substance Abuse Startup Challenge.'
TMT-Rx received a prestigious Phase I grant from the National Institutes of Health in 2021, supporting early-stage drug development.
In 2022, TMT-Rx was awarded NIDA STTR and SBIR FAST-track grants for drug development, supporting the advancement of its novel therapeutics.
TMT-Rx was selected for the I-Corps™ at NIH program and the NIH Fast-Track Small Business Innovation Research program, receiving over $1.3 million in funding to expedite commercialization of its biomedical technology.
TMT-Rx received a NIDA small business innovation research grant to investigate novel mechanisms for treatment of naloxone-resistant drug overdose.
Dr. Phillip Torralva was selected for the Yale Innovation to Impact Fellowship, a national program supporting commercialization of solutions to substance use disorder.